Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Janus Henderson Investors

Investor type Private Equity Firm


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 109
Average round size
The average size of a deal this fund participated in
Portfolio companies 95
Rounds per year 21.80
Lead investments 6
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 45
Key employees 13

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Therapeutics
  • Life Science

In 2017 was created Janus Henderson Investors, which is appeared as Corporate Investor. The leading representative office of defined Corporate Investor is situated in the London. The company was established in Europe in United Kingdom.

For fund there is no match between the location of its establishment and the land of its numerous investments - United States. Among the various public portfolio startups of the fund, we may underline BioNtech, Sojournix, Bigfoot Biomedical Besides, a startup needs to be aged 4-5 years to get the investment from the fund. The fund has no exact preference in a number of founders of portfolio startups. Among the most successful fund investment fields, there are Machine Learning, Pharmaceutical.

We also calculated 11 valuable employees in our database.

Deals in the range of 50 - 100 millions dollars are the general things for fund. The higher amount of exits for fund were in 2019. The top activity for fund was in 2019. The fund is constantly included in 2-6 deals per year. The real fund results show that this Corporate Investor is 23 percentage points more often commits exit comparing to other companies.

The usual cause for the fund is to invest in rounds with 6-7 partakers. Despite the Janus Henderson Investors, startups are often financed by Versant Ventures, Sectoral Asset Management, Jeffrey Brewer. The meaningful sponsors for the fund in investment in the same round are Cormorant Asset Management, Redmile Group, RA Capital Management. In the next rounds fund is usually obtained by Visionnaire Ventures, Silicon Valley Bank, Senvest Capital.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Janus Henderson Investors:
Typical Co-investors
Janus Henderson Investors is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Janus Henderson Investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Alipay China, Hangzhou, Zhejiang
Altera Capital Group Luxembourg, Luxembourg
Ballentine Capital Partners -
CMS Medical Venture Investment -
DC Investment Partners Mclean, United States, Virginia
DIA Management England, London, United Kingdom
East Gate Capital Management California, Los Altos, United States
Ecomobility Ventures France, Ile-de-France, Paris
Gladwyne Partners New York, New York, United States
Hook-Up Communications -
Kansai Electric Power Japan, Osaka, Osaka Prefecture
Narra Venture Capital Manila, Philippines
NP Investments Seoul, Seoul-t'ukpyolsi, South Korea
NVInvestments California, Santa Monica, United States California, Pasadena, United States
Planet 9 Capital -
Pritzker Foundation -
Rutherford Innovation Fund Canterbury, Christchurch, New Zealand
Tech Square Ventures Atlanta, Georgia, United States
Zhongda Tongshi Holdings Beijing, Beijing, China

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation


$26M16 Nov 2022 -


Health Care
$65M04 Nov 2022 San Diego, California, United States

Enliven Therapeutics

Life Science
$165M13 Oct 2022 Boulder, Colorado, United States

Disc Medicine

Health Care
$53M10 Aug 2022 Cambridge, Massachusetts, United States


Alternative Medicine
$40M13 Jun 2022 Boston, Massachusetts, United States


Health Care
Staffing Agency
$115M06 Apr 2022 Quincy, Massachusetts, United States

2seventy bio

$170M16 Mar 2022 -

Magnolia Medical Technologies

Health Care
Health Diagnostics
Medical Device
$46M16 Feb 2022 Seattle, Washington, United States

Parse Biosciences

Life Science
$41M15 Feb 2022 Seattle, Washington, United States
ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform

– ShouTi Inc. announced the close of a $100m Series B financing round.
– The round was led by BVF Partners. Additional new investors include Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Lilly Asia Ventures, Monashee Capital, Sage Partners, Stork Capital, Surveyor Capital (a Citadel company), TCG X, Terra Magnum Capital Partners, Woodline Partners, and co-founder and strategic partner Schrödinger.
– Existing investors also participated in the financing, including Eight Roads, F-Prime Capital Partners, Qiming Venture Partners, Sequoia Capital China, TF Capital and Wuxi AppTec.

Asher Bio Closes $108 Million Series B Financing

– Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, announced the closing of an oversubscribed Series B financing, which raised $108m.
– The financing was led by Wellington Management Company, and included new investors RA Capital Management, Janus Henderson Investors, Logos Capital, Marshall Wace and Alexandria Venture Investments, and, along with existing investors Third Rock Ventures, Invus, Boxer Capital of Tavistock Group, Mission BioCapital, and other undisclosed institutional investors.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Janus Henderson Investors?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: